Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Claims Edge In CAR-T; Says Suicide Switch Still A Dream

This article was originally published in Scrip

Executive Summary

Novartis AG believes the latest data for its chimeric antigen receptor T cell (CAR-T) therapy CTL019, presented at the American Society of Hematology (ASH) annual meeting, show it still has an edge over other CAR-T developers.

You may also be interested in...



China’s ICT Looks To Build On Promising CAR-T Results

Chinese biotech Innovative Cellular Therapeutics has reported promising results for its CAR-T cell immunotherapy in a small leukemia study, and the company is now planning to expand its clinical program into new indications including solid tumors, and to explore global markets.

Building The Talent Pipeline Starts With Access For All

Diversity in all forms is critical to innovation in health care, says AstraZeneca’s chief medical officer, Ann Taylor. In an exclusive interview, she talks about the company’s work in mentoring and education, and why tackling issues around diversity and inclusion must be driven by the C-suite alongside community initiatives. 

Snapshot: October Highlights

A selection of articles you might have missed from October 2020, including exclusive interviews with industry leaders and a deeper dive into the Femtech market.

Topics

UsernamePublicRestriction

Register

LL018264

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel